Evaluation Addressing Anhedonia, An Invisible Enemy in MDD: Neurobiology and Emerging Precision Treatments Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Brittany Albright, MD, MPH 5 4 3 2 1 Craig Chepke, MD, DFAPA 5 4 3 2 1 Emily Johnson, LPN 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Assess the burden and implications of anhedonia in MDD, as well as shortcomings associated with its conventional management 5 4 3 2 1 Evaluate the neurobiological rationale, mechanisms of action, and most recent clinical data associated with emerging precision treatments for anhedonia in MDD 5 4 3 2 1 Implement patient-centered strategies to evaluate anhedonia in MDD and optimize its management 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with Anhedonia on a monthly basis? 10 or fewer 20 30 40 50 or more Which of the following statements regarding the current burden and treatment of anhedonia in patients with MDD is most accurate? Anhedonia occurs in approximately 33% of patients with MDD Anhedonia occurs in approximately 75% of patients with MDD Anhedonia persists despite treatment in approximately 33% of patients with MDD Anhedonia persists despite treatment in approximately 75% of patients with MDD Which endogenous opioid receptor types are most clearly involved in regulating the reward processing mechanisms implicated in anhedonia? Kappa, delta, and mu Kappa, delta, and zeta Kappa, N/OFQ, and mu Kappa, N/OFQ, and zeta Which of the following selective kappa receptor antagonists have demonstrated specific efficacy against anhedonia in MDD, as measured by the SHAPS (Snaith-Hamilton Pleasure Scale)? ALKS-5461 and CVL-354 Aticaprant and navacaprant CVL-354 and aticaprant Navacaprant and ALKS-546 Which of the following selective kappa receptor antagonists was associated with increased ventral striatal activation during a reward anticipation task, along with improvement in anhedonia and reward learning, in a pioneering FAST-FAIL phase 2a trial? AKLS-5461 Aticaprant CVL-354 Navacprant How confident are you in your ability to detect and assess anhedonia in patients with MDD, using patient-centered communication strategies? Very confident Confident Somewhat confident Not very confident Not at all confident Based on my participation in this activity, I anticipate I will more often: (select all that apply) Use patient-centered communication strategies to improve detection and assessment of anhedonia in patients with MDD Use validated rating scales to assess anhedonia in patients with MDD Assess the effectiveness and limitations of currently available treatments for anhedonia in patients with MDD Differentiate residual anhedonia from antidepressant-induced emotional blunting in patients with MDD Evaluate the latest clinical data associated with selective kappa receptor antagonists under investigation for anhedonia in MDD Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Previous
